Navitoclax dihydrochloride is a small molecule commercialized by AbbVie, with a leading Phase III program in Post-Essential Thrombocythemia Myelofibrosis (Post-ET MF). According to Globaldata, it is involved in 37 clinical trials, of which 20 were completed, 15 are ongoing, and 2 were terminated. GlobalData uses proprietary data and analytics to provide a complete picture of Navitoclax dihydrochloride’s valuation in its risk-adjusted NPV model (rNPV). Buy the model here.
The revenue for Navitoclax dihydrochloride is expected to reach an annual total of $413 mn by 2033 in the US based off GlobalData’s Expiry Model. The drug’s revenue forecasts along with estimated costs are used to measure the value of an investment opportunity in that drug, otherwise known as net present value (NPV). Applying the drug’s phase transition success rate to remaining R&D costs and likelihood of approval (LoA) to sales related costs provides a risk-adjusted NPV model (rNPV). The rNPV model is a more conservative valuation measure that accounts for the risk of a drug in clinical development failing to progress.
Navitoclax dihydrochloride Overview
Navitoclax (ABT-263, RG7433) is under development for the treatment of primary myelofibrosis, metastatic melanoma, acute lymphoblastic leukemia, solid tumor, relapsed/refractory acute myeloid leukemia, non-small cell lung cancer, post polycythemia vera myelofibrosis, hepatocellular carcinoma, acute lymphocytic leukemia, lymphoblastic lymphoma and post-essential thrombocythemia myelofibrosis. It is administered orally. The drug candidate blocks the function of pro-survival Bcl-2 family proteins.
It was also under development for the treatment of small-cell lung cancer, metastatic hormone-refractory prostate cancer, hematologic malignancies including front-line chronic lymphocytic leukemia, relapsed or refractory chronic lymphocytic leukemia, myelofibrosis, primary myelofibrosis, post-polycythemia vera myelofibrosis, post-essential thrombocythemia myelofibrosis, polycythemia vera and essential thrombocythemia, B-cell chronic lymphocytic leukemia (CLL), relapsed diffuse large B-cell lymphoma and relapsed or refractory lymphoid malignancies and multiple myeloma.
AbbVie is a specialty biopharmaceutical company, which discovers, develops, manufactures, and commercializes drugs for the treatment of chronic and complex diseases. Its drugs are indicated for the treatment of metabolic and rheumatological diseases, neurological disorders, skin diseases, rheumatoid arthritis, pain related to endometriosis, pediatric Crohn’s disease, cancer, and other serious health conditions. AbbVie is also advancing its pipeline programs for the treatment of Crohn’s disease, Parkinson’s disease, viral diseases, wet AMD, various cancers, neurological disorders, aesthetics, and other autoimmune diseases. The company markets its products directly to wholesalers, distributors, health care facilities, government agencies, specialty pharmacies and independent retailers through its own distribution centers and public warehouses worldwide. AbbVie is headquartered in North Chicago, Illinois, the US.
The company reported revenues of (US Dollars) US$58,054 million for the fiscal year ended December 2022 (FY2022), an increase of 3.3% over FY2021. In FY2022, the company’s operating margin was 31.2%, compared to an operating margin of 31.9% in FY2021. In FY2022, the company recorded a net margin of 20.4%, compared to a net margin of 20.5% in FY2021. The company reported revenues of US$12,225 million for the first quarter ended March 2023, a decrease of 19.2% over the previous quarter.
For a complete picture of Navitoclax dihydrochloride’s valuation, buy the drug’s risk-adjusted NPV model (rNPV) here.